<DOC>
	<DOCNO>NCT00471133</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity DNA vaccine encode melanosomal antigen melanoma patient risk disease progression recurrence . In study , vaccine administer intramuscularly use device applies brief electrical field tissue site injection ( technique know electroporation ) . It expect device improve delivery vaccine . This study perform determine procedure administer safely capable induce immune response vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Melanoma DNA Vaccine Delivered Electroporation</brief_title>
	<detailed_description>This study design evaluate administration xenogeneic DNA vaccine encode melanosomal antigen tyrosinase vivo electroporation patient malignant melanoma . The objective study characterize safety immunogenicity DNA vaccine encode murine tyrosinase gene deliver administer intramuscularly use electroporation base TriGrid Delivery System ( Ichor Medical Systems ) . We assess nature , frequency , severity toxicity associate vaccination escalate pINGmuTyr dos expand enrollment expand enrollment Maximum Tolerated Dose ass immunologic response tyrosinase antigen . The hypothesis test procedure feasible safe induces immune response specific tyrosinase patient stage IIB-IV malignant melanoma .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients must document , histologically confirm malignant melanoma , American Joint Commission Cancer ( AJCC ) Stage IIB IV . Patients stage IIbIII disease eligible standard surgical care wide local excision appropriate lymph node sample . Patients stage IIb , IIc , III melanoma free disease surgical resection also eligible , refuse high dose Interferonalfa ( INTRON A ) recurrence Interferonalfa . Patients choroidal melanoma may participate fulfill one follow criterion : Basal diameter &gt; 16mm ; Height &gt; 8mm involvement ciliary body tumor . Patients must least 18 year age must capable understanding consent form give informed consent . Karnofsky Score &gt; 80 Life Expectancy &gt; 6 month HLAA1 , A2 , A24 , B35+ assess low resolution phenotyping White blood cell count ≥ 2,000/mm3 Platelet count ≥ 100,000/mm3 Neutrophil count ≥ 1,000/mm3 Hemoglobin ≥ 9.0 g/dL Serum AST ALT ≤ 2.5 time upper limit normal ( ULN ) Serum Bilirubin ≤ 2.0 mg/dL Serum Creatinine ≤ 2.0 mg/dL Serum Alkaline Phosphatase &lt; 2.5 time ULN Serum Creatine phosphokinase ( CPK ) &lt; 2.5 time ULN Documented metastases brain Clinical history HIV , HepB , HepC , and/or HTLV I . Active autoimmune disease vitiligo Patients previously immunize use tyrosinase DNA sequence , protein , peptide . Systemic immunosuppressive therapy ( corticosteroid , immunosuppressive drug ) within previous 28 day Surgery and/or radiotherapy within previous 28 day Chemotherapy and/or biotherapy within previous 28 day Participation investigational study within previous 28 day Patients cardiac demand pacemaker . Women pregnant &lt; 3 month post partum nursing . Women childbearing potential sexually active men must use appropriate contraception course study . Any concurrent medical condition opinion Principal Investigator coPrincipal Investigator 's would preclude study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>melanoma</keyword>
	<keyword>DNA vaccine</keyword>
	<keyword>tyrosinase</keyword>
	<keyword>electroporation</keyword>
</DOC>